Early stage IT and Healthcare Investing

Eiger BioPharmaceuticals

portfoliocompanies

company snapshot

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger's pipeline includes preclinical new chemical entities from internal discovery efforts, as well as repurposed clinical and approved drugs shown to possess novel antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.

website
www.eigerbio.com
Leadership
Follow The Company
Investment Team
David Cory, President & CEO
Facebook Google+ Twitter Email LinkedIn Share